RESUMEN
Platelets possess membrane receptors which mediate the aggregatory response to thromboxane A2 (TXA2) and prostaglandin H2 (PGH2). It has been observed recently that the affinities for a series of TXA2/PGH2 mimetics are decreased in crude human platelet membranes and solubilized membranes compared to intact washed platelets. The present study investigated the notion that platelets contain a substance that is released during platelet lysis that reduces the affinity of the TXA2/PGH2 receptor for agonists. The displacement of 9,11-dimethylmethano-11,12-methano-16-(3-iodo-4-hydroxyphenyl)-13, 14-dihydro-13 - aza-15 alpha beta-omega-tetranor-TXA2 ([125I]PTA-OH), a TXA2/PGH2 receptor antagonist, from its binding site in intact washed platelets by TXA2/PGH2 mimetics and antagonists was characterized in the presence or absence of the supernatant (50,000 g) obtained from sonicated platelets. In the presence of the supernatant, there was a significant (P less than 0.025) increase in the IC50 values for the TXA2/PGH2 mimetics U46619, SQ26655, and ONO11113. The increase in the IC50 for U46619 induced by the supernatant was abolished by either boiling or treating the supernatant with trypsin. The supernatant did not affect the Kd or Bmax of [125I]PTA-OH or the IC50 of the TXA2/PGH2 antagonist, SQ29548. Pretreatment of the platelets with the supernatant resulted in a significant (P less than 0.02) reduction in the aggregation response induced by U46619. Gel filtration (Sephacryl S200) of the supernatant revealed a fraction (molecular weight approximately 100,000 daltons) which significantly increased the IC50 for U46619 to displace [125I]PTA-OH from its binding site. Thus, human platelets appear to possess a protein(s) that is released into the supernatant upon sonication and inhibits the binding of TXA2/PGH2 agonists but not antagonists to their receptor. This protein may play a role in the regulation of platelet responses to the aggregatory stimuli TXA2/PGH2.
Asunto(s)
Plaquetas/metabolismo , Extractos Celulares/farmacología , Ácidos Grasos Monoinsaturados , Receptores de Prostaglandina/metabolismo , Extractos de Tejidos/farmacología , Ácidos Grasos Insaturados/farmacología , Humanos , Cinética , Agregación Plaquetaria/efectos de los fármacos , Endoperóxidos de Prostaglandinas Sintéticos/metabolismo , Endoperóxidos de Prostaglandinas Sintéticos/farmacología , Prostaglandina H2 , Prostaglandinas H/farmacología , Receptores de Tromboxanos , Receptores de Tromboxano A2 y Prostaglandina H2 , Tromboxano A2/análogos & derivados , Tromboxano A2/farmacología , Inhibidores de Tripsina/farmacologíaRESUMEN
The competition of [125I]-9, 11 dimethylmethano-11, 12 methano-16-(3-iodo-4-hydroxyphenyl)-13, 14-dihydro-13-aza 15 alpha beta-omega-tetranor-thromboxane A2 ([125I]-PTA-OH), a thromboxane A2/prostaglandin H2 receptor antagonist, with a series of thromboxane A2/prostaglandin H2 (TXA2/PGH2) mimetics for binding to the putative TXA2/PGH2 receptor in washed human platelets was studied. The rank order potency for the series of mimetics to compete with [125I]-PTA-OH for binding was compared with their rank order potency for induction of platelet aggregation. The rank order potency for the mimetics to compete with [125I]-PTA-OH for binding was ONO-11113 greater than SQ-26655 greater than U44069 greater than U46619 = 9, 11-azo PGH2 greater than MB28767. This rank order potency was highly correlated with their rank order potency for inducing platelet aggregation (r = 0.992). Changes in the intra or extracellular concentrations of Na+ did not have a significant effect on the competition between U46619 and [125I]-PTA-OH for binding to the putative receptor. In summary, it appears that these TXA2/PGH2 mimetics activate human platelets through the putative TXA2/PGH2 receptor.
Asunto(s)
Plaquetas/metabolismo , Endoperóxidos de Prostaglandinas Sintéticos/fisiología , Endoperóxidos de Prostaglandina/fisiología , Prostaglandinas H/fisiología , Tromboxano A2/análogos & derivados , Tromboxano A2/fisiología , Humanos , Técnicas In Vitro , Radioisótopos de Yodo , Agregación Plaquetaria/efectos de los fármacos , Prostaglandina H2 , Receptores de Prostaglandina/metabolismo , Sodio/sangre , Sodio/farmacología , Tromboxano A2/farmacologíaRESUMEN
Induction of cardiac work increased protein synthesis in hearts supplied glucose or a mixture simulating normal plasma levels of glucose, insulin, glucagon, lactate, and beta-hydroxybutyrate. During 2 h of perfusion, cardiac work did not accelerate protein synthesis in hearts supplied a mixture of glucose, lactate, and higher concentrations of insulin. Protein degradation was decreased by work in hearts supplied glucose. Nitrogen balance was negative in Langendorff-perfused hearts provided glucose, but was less so in working preparations. Nitrogen balance was zero or positive in working hearts provided the mixture simulating plasma or the mixture of glucose, lactate, and insulin. In Langendorff preparations, increased aortic pressure accelerated protein synthesis during the second hour of perfusion in hearts supplied glucose, glucose plus insulin, or pyruvate. When ventricular pressure development was prevented by ventricular draining or when drained hearts were arrested with tetrodotoxin, protein synthesis still increased as perfusion pressure was raised from 60 to 120 mm Hg. Oxygen consumption increased as aortic pressure was increased in drained, beating hearts, but was unaffected in arrested, drained hearts. These studies indicated that increased aortic pressure and its attendant stretch of the ventricular wall were the mechanical parameter most closely associated with faster rates of protein synthesis.
Asunto(s)
Corazón/fisiología , Miocardio/metabolismo , Proteínas/metabolismo , Animales , Presión Sanguínea , Técnicas In Vitro , Contracción Miocárdica , Perfusión , Biosíntesis de Proteínas , RatasRESUMEN
The patency rate of internal mammary artery grafts is reported to be better than that of saphenous vein grafts in myocardial revascularization operations. To identify a possible biochemical explanation for this phenomenon, we studied the production of prostacyclin by the internal mammary artery and saphenous vein in 11 patients. Segments of internal mammary artery and saphenous vein from each patient were incubated in Krebs-Henseleit buffer at 37 degrees C. After 15 minutes, the basal production of 6-keto-prostaglandin F1 alpha (prostacyclin metabolite) by the internal mammary artery was 152 +/- 39 pg/mg wet weight (mean +/- standard error of the mean), whereas the saphenous vein produced only 68 +/- 17 pg/mg (p less than 0.001). After 30 minutes, the internal mammary artery produced 179 +/- 42 pg/mg, whereas the saphenous vein produced 75 +/- 18 pg/mg (p less than 0.001). After the basal incubation period, the vessels were incubated with arachidonic acid (prostaglandin substrate) for 15 minutes. The internal mammary artery produced 49.4 +/- 9.9 pg/mg, whereas the saphenous vein produced only 22.6 +/- 9.8 pg/mg (p less than 0.01). These observations suggest that the capacity of the internal mammary artery to produce prostacyclin in both a basal and a stimulated state is greater than that of the saphenous vein. Since prostacyclin is a potent vasodilator and inhibitor of platelet function, these results provide a possible biochemical explanation for the clinically observed better patency rate of internal mammary artery grafts.
Asunto(s)
6-Cetoprostaglandina F1 alfa/biosíntesis , Arterias Mamarias/metabolismo , Vena Safena/metabolismo , Arterias Torácicas/metabolismo , Adulto , Análisis de Varianza , Ácidos Araquidónicos/farmacología , Endotelio/metabolismo , Humanos , Técnicas In Vitro , MasculinoRESUMEN
A binding site for the thromboxane A2/prostaglandin H2 (TXA2/PGH2) antagonist [125I]9,11-dimethylmethano-11, 12-methano-16-(3-iodo-4-hydroxyphenyl)-13,14-dihydro-13-aza-15 alpha beta-omega-tetranor-TXA2 to washed human platelets was studied. 9,11-Dimethylmethano-11, 12-methano-16-(3-iodo-4-hydroxyphenyl)-13,14-dihydro-13-aza-15 alpha beta-omega-tetranor-TXA2 competitively antagonized aggregation of washed human platelets induced by the TXA2/PGH2 mimetic U46619. A Schild analysis of the pharmacologic study revealed a pA2 of 8.08 and a slope of -1.12. The pA2 value yielded a Kd of 8 nM. The association rate constant (k1) for [125I]PTA-OH was 6.6 X 10(6)M-1 min-1 and the dissociation rate constant (k-1) was 1.82 X 10(-1), yielding a kinetically determined Kd (k-1/k1) of 27 nM. Scatchard analysis of [125I]PTA-OH binding to washed human platelets revealed one class of binding sites with a Kd of 21 +/- 5 nM and maximum binding of 42 +/- 6.4 fmol/10(7) platelets (N = 5) (2530 +/- 380 binding sites/platelet). Several TXA2/PGH2 receptor agonists and antagonists competed with [125I]PTA-OH for binding. For the four antagonists used in this study, the rank order of potency for displacing the ligand from its binding site correlated (r = 0.93) with the rank order of potency for their ability to inhibit U46619-induced aggregation in human platelet-rich plasma. The antiaggregatory prostaglandins prostaglandin F2 alpha, prostaglandin D2, and Iloprost also displaced the ligand, but only at concentrations considerably higher than that required to produce their pharmacologic effects.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Plaquetas/metabolismo , Receptores de Superficie Celular/metabolismo , Receptores de Prostaglandina/metabolismo , Tromboxano A2/análogos & derivados , Ácido 15-Hidroxi-11 alfa,9 alfa-(epoximetano)prosta-5,13-dienoico , Humanos , Técnicas In Vitro , Radioisótopos de Yodo , Cinética , Agregación Plaquetaria/efectos de los fármacos , Antagonistas de Prostaglandina/farmacología , Endoperóxidos de Prostaglandinas Sintéticos/farmacología , Prostaglandinas H/metabolismo , Receptores de Tromboxanos , Receptores de Tromboxano A2 y Prostaglandina H2 , Tromboxano A2/metabolismoRESUMEN
A binding site for the thromboxane A2/prostaglandin H2 (TXA2/PGH2) antagonist 125I-PTA-OH (9,11-dimethylmethano-11,12-methano-16-(4-methoxyphenyl)-13,14-dih ydro-13-aza-1 5 alpha beta-w-tetranor-TXA2) to washed canine platelets is described. 127I-PTA-OH competitively antagonized aggregation induced by the TXA2/PGH2 mimetic U46619. A Schild analysis of the pharmacologic study revealed pA2 of 7.97 and a slope of -0.95. The pA2 value yielded a Kd of 11 nM. Specific binding in Tris-NaCl buffer (pH 7.4) is not affected by extracellular Ca2+ or Mg2+ in concentrations up to 750 microM. The pH optimum for binding resides between 7.0 and 7.4. The association rate constant, k1, was 4.5 X 10(6) M-1 min-1, and the dissociation rate constant, k-1, was 1.45 X 10(-1) min-1, yielding a kinetically determined Kd (k-1/k1) of 32 nM. Scatchard analysis of I-PTA-OH binding to washed canine platelets revealed two classes of binding sites, a high affinity site (Kd = 24 nM, Bmax = 71 fmol/10(7) platelets) (4400 binding sites/platelet) and a low affinity site (Kd = 2.1 microM). Several TXA2/PGH2 receptor antagonists competed with specific 125I-PTA-OH binding, and the rank order of potency for displacing the ligand correlated (r = 0.97) with the rank order of potency for their ability to inhibit U46619-induced aggregation in canine platelet-rich plasma. Prostaglandins F2 alpha and E2 also displaced the ligand, but only at much higher concentrations. Binding of I-PTA-OH or the TXA2/PGH2 mimetic U46619 was unaffected by the aggregating agents epinephrine (10 microM) or ADP (5 microM). The similarity in the Kd values obtained kinetically, by equilibrium binding studies for the high affinity site and by Schild analysis, suggests that this high affinity site mediates TXA2/PGH2 induced platelet aggregation. In addition, the close correlation between the abilities of the antagonists to displace the ligand and to inhibit U46619-induced aggregation suggests that this site may represent a TXA2/PGH2 receptor.
Asunto(s)
Plaquetas/metabolismo , Receptores de Superficie Celular/metabolismo , Receptores de Prostaglandina/metabolismo , Tromboxano A2/metabolismo , Tromboxanos/metabolismo , Adenosina Difosfato/farmacología , Animales , Perros , Epinefrina/farmacología , Concentración de Iones de Hidrógeno , Cinética , Endoperóxidos de Prostaglandinas Sintéticos/metabolismo , Receptores de Tromboxanos , Receptores de Tromboxano A2 y Prostaglandina H2 , Relación Estructura-Actividad , Tromboxano A2/análogos & derivadosRESUMEN
The present study was undertaken to characterize thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors in platelets and blood vessels. Both human and canine platelet aggregation and saphenous vein contractions were induced by the stable TXA2/PGH2 mimetics (15S)-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5Z, 13E-dienoic acid (U46619) and 9,11-epithio-11,12-methano-TXA2 (ONO-11113). ONO-11113 was a more potent agonist than U46619 in the human saphenous vein but less potent in the platelet. These agonists were equipotent in the canine platelet but ONO-11113 was more potent in the saphenous vein. Platelet aggregation and saphenous vein contraction induced by U46619 were blocked in a dose-dependent manner by the TXA2/PGH2 receptor agonists 9,11-dimethylmethano-11,12-methano-16-phenyl-13,14-dehydro-13-aza- 15 alpha beta-omega-tetranor-TXA2 (ONO-11120), 9,11-dimethylmethano-11,12-methano-16-(4-hydroxyphenyl)-13,14-d ihy dro-13-aza-15 alpha beta-omega-tetranor-TXA2 (PTA-OH), 9,11-dimethylmethano-11,12-methano-16-(4-methoxyphenyl)-13,14-d ihy dro-13-aza-15 alpha beta-omega-tetranor-TXA2 (PTA-OM), 9,11-dimethylmethano-11,12-methano-16-(3-iodo-4-hydroxyphenyl-13,1 4-dihydro-13- aza-15 alpha beta-omega-tetranor-TXA2 (I-PTA-OH) and 9,11-dimethylmethano-11,12-methano-15-phenyl-13,14-dihydro-13-aza- 15 alpha beta-omega-pentanor-TXA2 [PTA-(omega-1)].(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Plaquetas/metabolismo , Vasos Sanguíneos/metabolismo , Receptores de Superficie Celular/metabolismo , Receptores de Prostaglandina/metabolismo , Animales , Perros , Humanos , Técnicas In Vitro , Contracción Muscular/efectos de los fármacos , Músculo Liso Vascular/efectos de los fármacos , Agregación Plaquetaria/efectos de los fármacos , Endoperóxidos de Prostaglandinas Sintéticos/farmacología , Receptores de Prostaglandina/efectos de los fármacos , Receptores de Tromboxanos , Receptores de Tromboxano A2 y Prostaglandina H2 , Vena Safena/efectos de los fármacos , Tromboxano A2/análogos & derivados , Tromboxano A2/farmacologíaRESUMEN
An overnight fast reduced RNA content and resulted in lower rates and efficiency of protein synthesis when rat hearts were perfused in vitro and supplied glucose as oxidizable substrate. Decreased efficiency of synthesis was associated with development of a block in peptide chain initiation in hearts of both fed and fasted rats. Provision of pyruvate increased the rate and efficiency of protein synthesis in fasted but not fed tissue, and partially overcame the initiation block in both groups. A mixture of glucose, pyruvate and insulin increased the efficiency of protein synthesis and decreased ribosomal subunit content to similar values in both groups of hearts. Noncarbohydrate substrates, including pyruvate, lactate, acetoacetate and beta-hydroxybutyrate, supported higher rates of protein synthesis than glucose in hearts of fasted, but not fed rats. However, mixtures of glucose and either pyruvate, acetoacetate or beta-hydroxybutyrate increased the synthetic rate in fed tissue. Provision of noncarbohydrate substrates increased energy availability, as indicated by higher creatine-P/creatine ratios in both groups of hearts, but the synthetic rate increased as a function of creatine-P/creatine ratio only in the fasted tissue. Octanoate and leucine accelerated protein synthesis and increased energy availability in the fed tissue. The mixtures of glucose and noncarbohydrate substrates or octanoate elevated glucose-6-P content. These studies indicate that an overnight fast decreased the capacity for protein synthesis and modified the regulation of synthesis by noncarbohydrate substrates.
Asunto(s)
Ayuno , Miocardio/metabolismo , Biosíntesis de Proteínas , Ácido 3-Hidroxibutírico , Acetoacetatos/metabolismo , Nucleótidos de Adenina/metabolismo , Animales , Caprilatos/metabolismo , Creatina/metabolismo , Glucosa/metabolismo , Glucosa-6-Fosfato , Glucofosfatos/metabolismo , Hidroxibutiratos/metabolismo , Insulina/metabolismo , Lactatos/metabolismo , Leucina/metabolismo , Masculino , Iniciación de la Cadena Peptídica Traduccional , Perfusión , Fosfocreatina/metabolismo , Piruvatos/metabolismo , Ratas , Ratas Endogámicas , Ribosomas/metabolismoRESUMEN
Mechanical parameters and intracellular mediators that may control protein synthesis have been studied in isolated rat hearts subjected to increased aortic pressure or induced to perform cardiac work. Elevation of aortic pressure from 60 to 120 mmHg in Langendorff preparations with glucose, glucose plus insulin, or pyruvate raised the rate of protein synthesis during the 2nd h of perfusion. These effects involved faster rates of both peptide chain initiation and elongation. In working hearts supplied glucose or glucose plus insulin, higher rate of synthesis were observed in both the 1st and 2nd h of perfusion, compared with Langendorff preparations perfused at 60 mmHg. Intracellular levels of glucose 6-phosphate, ATP/ADP ratio, adenylate energy charge, or creatine phosphate/creatine did not correlate with the rate of protein synthesis in beating control hearts. When ventricular pressure development was prevented by ventricular draining and hearts were arrested with tetrodotoxin, protein synthesis still increased as a function of perfusion pressure. Oxygen consumption increased as aortic pressure was raised in beating-drained hearts but was unaffected in arrested-drained hearts. These results indicate that intraventricular pressure development, cardiac contraction, oxygen consumption, glucose 6-phosphate, energy availability, and coronary flow could be dissociated from the stimulatory effect of higher aortic pressures on protein synthesis and suggested that stretch of the ventricular wall, as a consequence of increased aortic pressure, could be the mechanical parameter most closely related to the increase in protein synthesis.
Asunto(s)
Aorta/fisiología , Proteínas Musculares/biosíntesis , Miocardio/metabolismo , Animales , Metabolismo Energético , Glucosa-6-Fosfato , Glucofosfatos/análisis , Frecuencia Cardíaca , Masculino , Miocardio/análisis , Perfusión , Presión , Ratas , Ratas EndogámicasRESUMEN
Protein synthesis was accelerated in rat hearts that were provided insulin compared with provision of glucose or pyruvate alone or a mixture of glucose and pyruvate. The faster synthetic rates were accompanied by a reduction in numbers of ribosomal subunits, indicating that peptide chain initiation was accelerated relative to elongation/termination. In hearts supplied glucose, 65% of the maximal effect on protein synthesis was achieved by addition of 1.7 X 10(-10) M insulin, but significant effects on glucose uptake as well as on tissue contents of glucose 6-phosphate and creatine phosphate were obtained only with 7 X 10(-10) M insulin. Addition of glucose to perfusates containing pyruvate did not accelerate protein synthesis, although the glucose 6-phosphate content was raised. Similarly, the stimulatory effects of insulin on protein synthesis in hearts supplied pyruvate did not depend on changes in glucose 6-phosphate content, creatine phosphate/creatine, ATP/ADP, or adenylate energy charge. These studies indicate that insulin accelerated peptide-chain initiation and protein synthesis in rat heart by mechanisms independent of the hormone's effect on glucose or energy metabolism.